T-helper type 2 cell-directed therapy for asthma.
Asthma is a chronic inflammatory disease of the bronchial airways. Current research in humans and animals suggests that T-helper type 2 (Th2) cells and the cytokines they elaborate cause many of the pathophysiologic abnormalities characteristic of the disease. We review the evidence implicating Th2 cells in asthma and discuss the cellular and molecular mechanisms that control Th2 cell differentiation in the respiratory tract. Based on the steps in Th cell development, we discuss how traditional therapies can modulate Th2 cell function. Furthermore, we explore newer immunomodulatory strategies to inhibit Th2 cell effects, including therapies that may block Th2 cell differentiation, neutralize cytokines, and redirect immune responses towards Th1 and away from Th2.
Cohn
L
L
Section of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Yale University School of Medicine, 333 Cedar Street, PO Box 208057, 06520-8057, New Haven, CT, USA. lauren.cohn@yale.edu
Ray
A
A
D000818:Animals; D001249:Asthma / Q000188:drug therapy* / Q000276:immunology*; D002454:Cell Differentiation; D004195:Disease Models, Animal; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D007249:Inflammation; D006377:T-Lymphocytes, Helper-Inducer / Q000276:immunology*